Exchange from Beraprost to Selexipag study

Exchange from Beraprost to Selexipag study - EXCEL study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026239

Enrollment

100

Registered

2017-02-21

Start date

2016-11-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PAH(Nice classification group 1) Patients with and without ERA and/or PDE5i/sGC therapy WHO FC 2or3 6MWD of 150-450m mPAP>=25mmHg Patients received treatment with Beraprost for at least 3 months

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Improvement of pulmonary vascular resistance	—

Countries

Japan

Contacts

Public ContactYuichi Tamura

International University of Health and Welfare, Mita Hospital Cardiovascular internal medicine

u1@iuhw.ac.jp03-3451-8121

Outcome results